ClinicalTrials.gg
RecruitingNCT06142240Updated Nov 21, 2023

Efficacy of Two Therapeutic Exercise Modalities for Patients With Persistent COVID

An interventional study of exercise programe in Persistent COVID-19, sponsored by Facultat de ciencies de la Salut Universitat Ramon Llull. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-11-21.

Sponsored by Facultat de ciencies de la Salut Universitat Ramon Llull · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Jun 2023, registered Nov 2023).
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain — 13 open to participants now, 16 under way, 1 of them phase 3. Post-Acute COVID-19 Syndrome · Spain.

Planned enrollment
29th of 39
40 · median 60
Started
2023
with 11 others
No phase
31 of 52
7 open now
Primary completion
2025-04
later than 4 of 15 live
Registered
31st of 52
by date

Among the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, this one is the 29th largest by planned enrollment of the 39 interventional ones that give a count, is one of 12 that started in 2023, is one of 31 with no phase, reaches primary completion later than 4 of the 15 other live ones, and was the 31st registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

13 of the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, or all of them as a file.
02

Study summary

Symptoms of long-standing sequelae and complications of COVID-19, termed Long COVID19 or persistent COVID, have been reported worldwide. However, the etiology underlying the prolonged or fluctuating symptomatology is limited and there is no uniform and widely accepted definition.Patients describe persistent COVID as a fluctuating disease with variable and persistent symptoms.Most of the effects correspond to clinical symptoms such as fatigue, headache, arthralgias, hyposmia, gustatory sensations, etc. Fatigue is the most common and prolonged symptom of persistent COVID. Knowledge of the pathophysiological mechanisms of fatigue in COVID-19 disease, as well as the therapeutic approach, remains limited due to the relatively recent onset of this pathology. In particular, muscle strength training has been shown to improve muscle function and fatigue, not only during treatment, but also at long-term follow-up.

Read the detailed description

Objective: To evaluate the effects on the perception of fatigue in patients with persistent COVID, who undergo a supervised and directed therapeutic exercise program in a health center compared to a home therapeutic exercise program.

Methods: Randomized pilot study. Subjects who are included in the study will perform a therapeutic exercise program which will last 8 weeks and 2 sessions per week of 1h duration. The participants assigned to the supervised group will carry out the program at the health center, while the participants assigned to the home group will receive telematic supervision (by videoconference). Both groups will be under the supervision of the assigned physiotherapist.

The components that will form part of the exercise program will be: muscular strength training and continuous-variable aerobic training or HIIT type with loads between 70-90% of maximum heart rate. The main variables are fatigue.

03

Conditions studied

  • Persistent COVID-19
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients diagnosed with LongCOVID19 or persistent COVID19.
  • Agree to participate and sign the form.

Exclusion criteria

Exclusion Criteria:

  • Patients with comorbidities associated with having fatigue (e.g. cancer survivors, severe cardiovascular or respiratory disease prior to persistent COVID).
  • Taking medication of drugs that may interfere with the perception of fatigue.
  • Patients with mental disorders or cognitive impairment prior to persistent COVID.
  • Patients who regularly practice intense sports (>4h/week).
  • Any illness that may condition understanding and compliance with the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    programe at the health centre

    Subjects who are included in the study will perform a therapeutic exercise programme which will have a duration of 8 weeks and 2 sessions per week of 1h duration. Participants assigned to the supervised group will perform the programme at the health centre

    Other: exercise programe

  • Experimental
    programe at the health home

    Subjects who are included in the study will perform a therapeutic exercise programme which will have a duration of 8 weeks and 2 sessions per week of 1h duration. Participants assigned to the to the home group will receive telematic supervision (via videoconference).

    Other: exercise programe

Interventions

  • Otherexercise programe

    The components of the exercise programe will be: muscle strength training and continuous-variable aerobic training or HIIT with loads between 70-90% of maximum heart rate. The aerobic training will last about 30 minutes and will then be completed with muscle training of the upper and lower limbs with loads determined according to the perception of effort (loads around 50-70%). The sessions will be monitored with pulse oximetry (heart rate and oxygen saturation), perception of fatigue and sensation of suffocation (Borg scale). The intensity of each component of the programme will be individualised according to the conditions of each subject. Adherence to the programme will be recorded as successful when participation in the sessions is greater than 80% of the total number of sessions.

06

What researchers measure

Primary outcomes

  1. Fatigue

    this is the main variable of the study. It will be measured using the self-report scale "Fatigue Impact Scale" (FIS) (Fisk et al., 1994), which assesses the perception of functional limitation caused by fatigue in three areas: physical, cognitive and psychosocial. Range 0 (no problem) to 4 (extrem problem)

    Time frame: hour

Secondary outcomes

  1. Exercise capacity

    will be assessed using the six-minute walk test (6MWT). In the 6MWT we will measure the total number of metres the patient is able to walk for 6 minutes. The test will be performed in an indoor corridor of 30m distance, repeated 2 times with a pause of at least 30min between them.

    Time frame: hour

Other outcomes

  1. Pulmonary function

    Spirometry will be measured using an EasyOneTM World Spirometer (ndd Medical Technologies, Zurich, Switzerland). * Forced spirometry (FEV1, normal value 70-75% mesure Litres) percentage of the total exhaled volume in the first second * Forced vital capacity (FVC, normal value 80% mesure Litres ) It is made up of the sum of total volume, inspiratory reserve volume and expiratory reserve volume. The variables will be included in the analysis and will be performed following ATS/ERS recommendations (19).

    Time frame: hour

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Apr 2025, 22 months after the start.

Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 22 months is above that.

Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2023
First posted
Nov 21, 2023
StartActual
Jun 1, 2023
Primary completionEst.
Apr 1, 2025
CompletionEst.
Sep 1, 2025
Last update
Nov 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06142240
Lead sponsor
Facultat de ciencies de la Salut Universitat Ramon Llull
Responsible party
Sponsor
First posted
Nov 21, 2023
Start date
Jun 1, 2023
Primary completion
Apr 1, 2025 (estimated)
Completion
Sep 1, 2025 (estimated)
Last update
Nov 21, 2023

Study contacts

Pedro Victor López Plaza
Contact
pedrovictorlp@blanquerna.url.edu
932 53 32 56
Victoria Alcaraz Serrano
Contact
victoriaas@blanquerna.url.edu
932 53 32 56

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion